research Ovary And Uterus Related Adverse Events Associated With Statin Use: An Analysis Of The FDA Adverse Event Reporting System
Statins may be linked to reproductive organ conditions, and their risks should be monitored.
Search
forLearn
0 / 0 results — no results
Research
5 / 113 results 
research Mesenchymal Stem Cells Isolated From Equine Hair Follicles Using A Method Of Air-Liquid Interface
Scientists found a new, less invasive way to get stem cells from horse hair for veterinary medicine.
research PSS21 Gap Analysis for Patient-Reported Outcomes Measures for Alopecia
No current patient-reported outcome measure fully meets FDA requirements for alopecia treatments.
research PSS20 Mediation Modeling and Measurement Characteristics of the Itch Severity Score from a Phase 2B Trial of Oral CP-690-550 in Patients with Moderate-to-Severe Plaque Psoriasis
CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
research Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study
Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.
Community Join
3 / 3 resultscommunity Finasteride/dut. causes NAFLD,IR,diabetes,kidney dysfunction is it correct.
Hair loss discussion mentions treatments like Finasteride, Dutasteride, and Minoxidil. Users share experiences, side effects, and advice on using these treatments.
community 7 months update - 1 mg fin, topical min
A user's 7-month progress using 1 mg finasteride and topical minoxidil, with no side effects from the finasteride, achieving baby hairs on the hairline and other positive results. Other users have discussed different treatments such as microneedling and supplements, providing advice and encouragement to the poster.
community No, Finasteride as a treatment for MPB was not an "accident"
Finasteride was intentionally developed to treat BPH and later approved for male pattern baldness (MPB) due to its 5AR inhibition effects. The delay in MPB approval was due to concerns about off-label use for female hirsutism and the prioritization of treating a more debilitating condition.